Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19329908 | 0.84 | — | — | |
| SCHEMBL1268488 | 0.78 | DNM1 (0.39) | ALDH1A1MAPTDNM1FDPSCA2 | |
| SCHEMBL5969229 | 0.76 | — | — | |
| SCHEMBL2969238 | 0.69 | — | — | |
| SCHEMBL1309252 | 0.69 | — | — | |
| SCHEMBL509074 | 0.67 | — | — | |
| SCHEMBL14571190 | 0.67 | DNM1 (0.45) | ALDH1A1MAPTDNM1FDPSCA2 | |
| SCHEMBL14660353 | 0.67 | — | — | |
| SCHEMBL5909372 | 0.67 | ANPEP (0.41) | ANPEPALDH1A1DNM1FDPSCA2 | |
| SCHEMBL14212969 | 0.67 | ANPEP (0.41) | ANPEPALDH1A1DNM1FDPSCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812360-B2 | TREATING DIABETES MELLITUS BY ADMINISTERING A FRUCTOSAMINE OXIDASE INHIBITOR SUCH AS A HYDRAZINE COMPOUND, N-ALPHA-CBZ-L-ARGININE OR ACETYLPENICILLAMINE. | NIPPON SHOKUBAI CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| EP-1338601-A1 | PROCESS FOR PREPARING BIS(FLUOROARYL)BORON DERIVATIVES | Nippon Shokubai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030045507-A1 | Process for preparing bis(fluoroaryl)boron derivatives | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045507-A1 | Process for preparing bis(fluoroaryl)boron derivatives | FHIT, BLVRB, NRAS | ANPEP 2978/4885ALDH1A1 2358/4885MAPT 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.